Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 958-965

  Boissel, Laurent ^a   Betancur, Monica ^a   Lu, Weiquan ^a   Wels, Winfried S ^b   Marino, Teresa ^a   Van Etten, Richard A ^a   Klingemann, Hans ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

CAR; lentiviral vector; lymphoid malignancies; NK cells; NK 92

Indexed keywords

LENTIVIRUS VECTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA;

ANTIGEN RECOGNITION; ARTICLE; BLOOD CELL; CELL POPULATION; CELL SELECTION; CHIMERA; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; ELECTROPORATION; ENRICHMENT CULTURE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LENTIVIRINAE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UMBILICAL CORD BLOOD; VIRAL GENE DELIVERY SYSTEM;

CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; ELECTROPORATION; HUMANS; KILLER CELLS, NATURAL; LENTIVIRUS; LYMPHOCYTES; RECEPTORS, ANTIGEN; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; TRANSFECTION; TRANSGENES;

EID: 84859990187     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.634048     Document Type: Article

References (40)

1. Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2010;23:133-143.
2. Tsimberidou AM. Ofatumumab in the treatment of chronic lymphocytic leukemia. Drugs Today (Barc) 2010;46:451-461.
3. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptormodifi ed T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-733.
4. Imai C, Iwamoto S, Campana D. Genetic modifi cation of primary natural killer cells overcomes inhibitory signals and induces specifi c killing of leukemic cells. Blood 2005;106:376-383. (Pubitemid 40967217)
5. Kruschinski A, Moosmann A, Poschke I, et al. Engineering antigenspecifi c primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci USA 2008;105:17481-17486.
6. Uherek C, Tonn T, Uherek B, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in effi cient and selective tumor cell destruction. Blood 2002;100:1265-1273. (Pubitemid 34864281)
7. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22:1136-1151. (Pubitemid 41095048)
8. Verheyden S, Demanet C. NK cell receptors and their ligands in leukemia. Leukemia 2008;22:249-257. (Pubitemid 351250528)
9. Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011;132:315-325.
10. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051-3057.
11. Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110:433-440. (Pubitemid 47026866)
12. Spanholtz J, Preijers F, Tordoir M, et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One 2011;6:e20740.
13. Micucci F, Zingoni A, Piccoli M, et al. High-effi cient lentiviral vector-mediated gene transfer into primary human NK cells. Exp Hematol 2006;34:1344-1352. (Pubitemid 44374838)
14. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994;8:652-658. (Pubitemid 24133034)
15. Yan Y, Steinherz P, Klingemann HG, et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res 1998;4:2859-2868. (Pubitemid 28523516)
16. Maki G, Klingemann HG, Martinson JA, et al. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res 2001;10:369-383. (Pubitemid 32673241)
17. Tonn T, Becker S, Esser R, et al. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001;10:535-544. (Pubitemid 32756192)
18. Arai S, Meagher R, Swearingen M, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: aphase I trial. Cytotherapy 2008;10:625-632.
19. Romanski A, Bug G, Becker S, et al. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol 2005;33:344-352. (Pubitemid 40261316)
20. Romanski A, Uherek C, Bug G, et al. Re-targeting of an NK cell line (NK92) with specifi city for CD19 effi ciently kills human B-precursor leukemia cells. Blood 2004;104(Suppl. 1): Abstract 2747.
21. Boissel L, Betancur M, Wels WS, et al. Transfection with mRNA for CD19 specifi c chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res 2009;33:1255-1259.
22. Mül ler T, Uherek C, Maki G, et al. Expression of a CD20-specifi c chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 2008;57:411-423. (Pubitemid 350295385)
23. D'Costa J, Mansfi eld SG, Humeau LM. Lentiviral vectors in clinical trials: current status. Curr Opin Mol Th er 2009;11:554-564.
24. Matrai J, Chuah MK, VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol Th er 2010;18: 477-490.
25. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor eff ects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
26. Th omas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003;4:346-358. (Pubitemid 36538359)
27. Li L, Liu LN, Feller S, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Th er 2010;17:147-154.
28. Tohda S, Sakashita C, Fukuda T, et al. Establishment of a double Philadelphia chromosome-positive acute lymphoblastic leukemiaderived cell line, TMD5: eff ects of cytokines and diff erentiation inducers on growth of the cells. Leuk Res 1999;23:255-261. (Pubitemid 29083382)
29. Boissel L, Tuncer HH, Betancur M, et al. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant 2008;14:1031-1038.
30. Weitzman J, Betancur M, Boissel L, et al. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:1361-1368.
31. Williams BA, Wang XH, Keating A. Clonogenic assays measure leukemia stem cell killing not detectable by chromium release and fl ow cytometric cytotoxicity assays. Cytotherapy 2010;12:951-960.
32. Klingemann HG. Natural killer cell-based immunotherapeutic strategies. Cytotherapy 2005;7:16-22.
33. Berry LJ, Moeller M, Darcy PK. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. Tissue Antigens 2009;74:277-289.
34. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specifi city by introducing a tumor-specifi c chimeric antigen receptor. Blood 2011;116:1035-1044.
35. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116:4099-4102.
36. D'Arena G, Dell' Olio M, Musto P, et al. Morphologically typical and atypical B-cell chronic lymphocytic leukemias display a diff erent pattern of surface antigenic density. Leuk Lymphoma 2001;42:649-654. (Pubitemid 32782771)
37. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998;51: 364-369. (Pubitemid 28289122)
38. Berg M, Lundqvist A, McCoy P Jr, et al. Clinical-grade ex vivoexpanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009;11:341-355.
39. Klingemann HG, Martinson J. Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy 2004;6:15-22. (Pubitemid 38325115)
40. Berg M, Childs R. Ex-vivo expansion of NK cells: what is the priority-high yield or high purity? Cytotherapy 2010;12:969-970.